Patient Centered Peostate Cancer Diagnosi &Treatment

WASHINGTON, D.C. (January 23, 2012) - The Patient-Centered Outcomes Research
Institute (PCORI) today released for public comment a first draft of its
National Priorities for Research and Research Agenda, which will be used to
guide funding announcements for comparative clinical effectiveness research
that will give patients and those who care for them the ability to make
better-informed health decisions.



The 53-day public comment period, which will end in mid-March, will be used
to solicit feedback and revise the priorities and agenda before a final
version of each is adopted by PCORI's Board of Governors.



"We want to hear from patients, caregivers, providers and the wider health
care community on whether our draft priorities and initial research agenda
capture the broad areas where more evidence-based information is needed to
make better decisions," said PCORI Board Chair Eugene Washington, M.D.,
M.Sc. "This is a major milestone in our work as we continue to collaborate
with all stakeholders and to build on the work of others for what we expect
will be the most patient-centered research agenda yet."



The draft National Priorities for Research identifies five areas where
comparative effectiveness research is needed to support decision-making:



    Assessment of Options for Prevention, Diagnosis, and Treatment

    Improving Health Care Systems;

    Communication and Dissemination Research;

    Addressing Disparities; and

    Accelerating Patient-Centered Outcomes Research and Methodological
Research.



_______________________________________________
ProstateCancerAction mailing list
ProstateCancerAction@malecare.com
http://mail.malecare.com/mailman/listinfo/prostatecanceraction_malecare.com

New Provenge Clinical Trial

Clinical trial - NO placebo:Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Currently recruiting in Denver, Seattle, and Virginia Beach.  Contact info in link above.

Basic Eligibility Criteria:

• Metastasis on Bone Scan or CT within 28 days before starting trial
• PSA 2.0 or greater
• Testosterone less than or equal to 50
• Evidence of cancer progression
• NO metastases to lung, liver, or brain
• NO Xgeva (denosumab) within the last 3 months
• NO treatment within the last 28 days with ANY of the following:
  • Proscar
  • Avodart
  • saw palmetto
  • DES
  • Megace
  • Casodex or Eulexin or Nilutamide
  • ketoconazole

 

This trial would give Zytiga (abiraterone) access for free to men who have NOT had chemo. Also access to PROVENGE no matter what your insurance policy is.  Print and discuss with your physician(s).

Hope this helps someone,

 

Jan Manarite
PCRI Senior Educational Facilitator

(310) 743-2110  or(239) 395-0995  DirectThe PROSTATE CANCER RESEARCH INSTITUTE is a registered non-profit organization. Visit us at www.PCRI.org
I am a prostate cancer researcher and advocate, not a medical professional. Information I share with you is to help expand your knowledge for discussion with your own physicians
and should not be considered actual medical advice.

Hi to All,

This trial looks promising.

Dick Gillespie 703/497-0628 

=

New Global Research Studies,elm*pc Studies

Us TOO Homepage | Donate | View Message in Your Browser | Unsubscribe/Edit Preferences | Forward This Email

February 22, 2012 Dear Dick, As a reminder, two global research studies, called the elm•pc studies, are seeking men with metastatic castration-resistant prostate cancer to participate in the effort to evaluate a new investigational oral medication, TAK-700, given with prednisone. The studies will help determine if TAK-700, given with prednisone, can lengthen the lives of men with metastatic castration-resistant prostate cancer compared to prednisone alone. Men enrolled in either study will be assigned to one of two groups: those who will receive the investigational oral medication, TAK-700, with prednisone, and those who will be treated with prednisone alone. Prednisone is asteroid commonly used to treat advanced prostate cancer. TAK-700, an investigational oral lyase inhibitor, is being studied for individuals with metastatic prostate cancer. The elm•pc studies are being conducted by Millennium: The Takeda Oncology Company. To learn more about the elm•pc studies call 1-855-493-5672 or visit  www.elmpctrials.com. Please feel free to forward this message along to other men you know who are dealing with painful prostate cancer, or to physicians who might be interested in sharing the information with their other patients. Thank you in advance for your consideration and participation.

Thought you might like to see these!!! Comments made in the year 1957: "I'll tell you one thing, if things keep going the way they are, it's going to be impossible to buy a week's groceries for $20." "Have you seen the new cars coming out next year? It won't be long before $5000 will only buy a used one."